NCT07218432View on ClinicalTrials.gov

A Study of the TheraBionic P1 Device in Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2028

Conditions
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIAHormone Receptor Positive TumorHER2-negative Breast Cancer
Interventions
DEVICE

TheraBionic P1 Device

Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day and in the evening prior to surgical resection of early stage breast cancer.

Trial Locations (1)

48201

RECRUITING

Karmanos Cancer Institute, Detroit

All Listed Sponsors
lead

Barbara Ann Karmanos Cancer Institute

OTHER